An analysis suggests GLP-1 receptor agonist drugs show no strong signal of psychiatric harm, though one unexplained finding warrants continued monitoring. The reassurance matters given wide patient exposure and prior concerns about mood effects. Clinicians are advised to remain vigilant for rare or subgroup-specific neuropsychiatric events.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.